Kopran Ltd
Kopran Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Kopran Ltd Q2 FY27 key numbers
- Revenue
- Revenue from Operations for Q2 FY 2026-27: Rs. 21,126 lakhs.
As stated in Kopran Ltd's Q2 FY27 investor presentation · published 3 Nov 2026. Reported figures, not investment advice.
Based on Kopran Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from Operations for Q2 FY 2026-27: Rs. 21,126 lakhs (Page 5) EBITDA for Q2 2026-27: Rs. 1,822 Lakhs, up from Rs. 299 Lakhs in Q2 2025-26 (YoY increase).
From Kopran Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.
How did Kopran's revenue grow in the September 2026 quarter?
What happened to Kopran's margins in Q2 FY27?
See what Kopran Ltd said on profitability & margins — free account, 30 seconds.
What capex is Kopran planning?
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Kopran raising money or cutting debt?
See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Kopran's order book?
See what Kopran Ltd said on order book & pipeline — free account, 30 seconds.
Kopran Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹234 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kopran's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Emcure Pharma (Q2 FY27)
Q2FY27 Revenue from Operations: INR 28,205 Mn, up 24.3% YoY (Page 9). Key investor presentation takeaways from Emcure Pharmaceuticals Ltd's Q2 FY27 investor pre
- SPARC (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026, is ₹3,003 lakhs, up from ₹786 lakhs in the quarter ended September 30, 2025. Key results state
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Kopran Ltd Q2 FY27 results?
Revenue from Operations for Q2 FY 2026-27: Rs. 21,126 lakhs (Page 5) EBITDA for Q2 2026-27: Rs. 1,822 Lakhs, up from Rs. 299 Lakhs in Q2 2025-26 (YoY increase).
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 46.8 with a market cap of ₹1,171 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kopran Ltd planning capital expenditure?
Focus on capacity expansion is highlighted as a strategic imperative (Page 15). - Emphasis on process improvements and atomization of packing lines in formulations without quantification (Page 15).
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.